These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15871733)

  • 1. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists.
    Milani S; Djavan B
    BJU Int; 2005 Jun; 95 Suppl 4():29-36. PubMed ID: 15871733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
    Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
    Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
    Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
    Dunn CJ; Matheson A; Faulds DM
    Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of medical treatments for benign prostatic hyperplasia on sexual function.
    Giuliano F
    BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial choices and final outcomes in lower urinary tract symptoms.
    Speakman MJ
    Eur Urol; 2001; 40 Suppl 4():21-30. PubMed ID: 11786676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Blockers for benign prostatic hyperplasia: the new era.
    Lepor H; Kazzazi A; Djavan B
    Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
    Fonseca J; Martins da Silva C
    Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
    Nickel JC
    Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.